effect of high dose of atorvastatin after angioplasty in patients with stable angina

Comparing effectiveness of high dose atorvastatin versus low dose atorvastatin in cardiovascular outcome after Percutaneous Coronary Intervention (PCI) in patients with stable angina

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016060418741N2

Enrollment

469

Registered

2016-06-14

Start date

2012-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stable angina. Chronic ischaemic heart disease

Interventions

Intervention 1: Intervention group: atorvastatin- tablet 40 mg twice per day up to 6 month. Intervention 2: Control group: standard treatment- atorvastatin- tablet 10 mg twice per day up to 6 month.

Treatment - Drugs

Intervention group: atorvastatin- tablet 40 mg twice per day up to 6 month

Control group: standard treatment- atorvastatin- tablet 10 mg twice per day up to 6 month

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with stable angina that nominated for coronary angioplasty Exclusion criteria: acute coronary syndrome (unstable angina, non ST elevation myocardial infarction, ST elevation myocardial infarction); bare stent angioplasty; balloon angioplasty; angioplasty on saphenous vein graft; liver disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Major adverse cardiovascular and cerebrovascular events. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;All cause mortality. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;Myocardial infarction. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;Stroke. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;Target lesion revascularization. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;Target vessel revascularization. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;Acute coronary syndrome. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;At least 3 times increase of liver enzyme. Timepoint: 3 , 6 month after procedure. Method of measurement: miligram per deciliter.;At least 3 times increase of mascular enzyme. Timepoint: 3 , 6 month after procedure. Method of measurement: miligram per deciliter.	—

Measure

Time frame

Major adverse cardiovascular and cerebrovascular events. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;All cause mortality. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;Myocardial infarction. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;Stroke. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;Target lesion revascularization. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;Target vessel revascularization. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;Acute coronary syndrome. Timepoint: 6 month after procedure. Method of measurement: Questionnaire.;At least 3 times increase of liver enzyme. Timepoint: 3 , 6 month after procedure. Method of measurement: miligram per deciliter.;At least 3 times increase of mascular enzyme. Timepoint: 3 , 6 month after procedure. Method of measurement: miligram per deciliter.

—

Secondary

Measure	Time frame
Low density lipoprotein (LDL). Timepoint: end of study. Method of measurement: miligram per deciliter.;Total cholesterol. Timepoint: end of study. Method of measurement: miligram per deciliter.;High density lipoprotein (HDL). Timepoint: end of study. Method of measurement: miligram per deciliter.;Triglyceride. Timepoint: end of study. Method of measurement: miligram per deciliter.;Total cholesterol to HDL. Timepoint: end of study. Method of measurement: miligram per deciliter.	—

Measure

Time frame

Low density lipoprotein (LDL). Timepoint: end of study. Method of measurement: miligram per deciliter.;Total cholesterol. Timepoint: end of study. Method of measurement: miligram per deciliter.;High density lipoprotein (HDL). Timepoint: end of study. Method of measurement: miligram per deciliter.;Triglyceride. Timepoint: end of study. Method of measurement: miligram per deciliter.;Total cholesterol to HDL. Timepoint: end of study. Method of measurement: miligram per deciliter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTohid Rahimi

Mazandaran University of Medical Sciences

t.rahimi59@yahoo.com+98 11 3332 4002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026